Primary Progressive Multiple Sclerosis (PPMS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Primary Progressive Multiple Sclerosis (PPMS) Market Outlook

Thelansis’s “Primary Progressive Multiple Sclerosis (PPMS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Progressive Multiple Sclerosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Progressive Multiple Sclerosis (PPMS) Overview

Primary progressive multiple sclerosis (PPMS) stands out among the various forms of multiple sclerosis due to its unique characteristic of presenting as a progressively worsening condition from the onset of the disease. In contrast to relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS), where symptoms come and go in episodes, PPMS is marked by a continuous deterioration of neurological function. Approximately 10% of all multiple sclerosis patients receive a diagnosis of PPMS, making it a relatively less common but impactful subtype of the disease. The precise cause of PPMS remains unknown, adding to the complexity of understanding and treating this form of multiple sclerosis. Patients typically receive a PPMS diagnosis in their mid-to-late 30s, a stage of life where the impact on daily functioning and quality of life can be particularly challenging. Noteworthy is the observation that primary progressive multiple sclerosis may exhibit a higher prevalence in men compared to the relapsing/remitting disease group. This potentially leads to an equal male-to-female sex ratio or even a slight male preponderance among individuals with PPMS. Symptomatically, individuals living with PPMS often experience manifestations similar to those with relapsing forms of multiple sclerosis. However, weakness in leg muscles and difficulties with walking tend to be more prevalent in PPMS, further distinguishing it from other subtypes. One of the challenges in managing PPMS is the need for more understanding of its immunological findings compared to other forms of the disease. This knowledge gap underscores the need for further research to elucidate the underlying mechanisms driving the progressive nature of PPMS.

• In March 2017, the US Food and Drug Administration approved Ocrevus (ocrelizumab) to address relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS) in adult patients. This is the first drug approved by the FDA for PPMS.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: